development into hashimoto's thyroiditis; serious endocrine disruption; subacute thyroiditis; throat sore/ pulsations in the throat; chilliness/ constant chills; strong heat; lump formation; inappropriate schedule of vaccine administered; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the ra-web. regulatory number: it-minisal02-843660. a 45 year-old female patient received bnt162b2 (comirnaty, solution for injection), intramuscular, administration date 14jul2021 (lot number: unknown) as dose 2, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: comirnaty (dose 1, lot unknown.), administration date: 19feb2021, for covid-19 immunization. the following information was reported: thyroiditis subacute (disability) with onset 01aug2021, outcome "not recovered", described as "subacute thyroiditis"; oropharyngeal pain (disability) with onset 01aug2021, outcome "not recovered", described as "throat sore/ pulsations in the throat"; feeling cold (disability) with onset 01aug2021, outcome "not recovered", described as "chilliness/ constant chills"; feeling hot (disability) with onset 01aug2021, outcome "not recovered", described as "strong heat"; sensation of foreign body (disability) with onset 01aug2021, outcome "not recovered", described as "lump formation"; autoimmune thyroiditis (medically significant), outcome "unknown", described as "development into hashimoto's thyroiditis"; endocrine disorder (non-serious), outcome "unknown", described as "serious endocrine disruption"; inappropriate schedule of product administration (non-serious) with onset jul2021, outcome "unknown", described as "inappropriate schedule of vaccine administered". therapeutic measures were taken as a result of thyroiditis subacute, feeling hot, sensation of foreign body. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected